Welcome to FreedomWorks Foundation’s tenth regulatory review of 2019! Our Regulatory Action Center proudly updates you with our favorite tidbits from the swamp. We want to smash barriers between bureaucracy and the American people by delivering regulatory news straight to FreedomWorks activists. Check back in two weeks for the next edition.

FreedomWorks is proud to honor Rep. Chip Roy (R-Texas) as the member of the month for June 2019. He serves in the House of Representatives to represent Texas’ 21st Congressional District, which spans to the north and west of Austin, Texas. But in reality, Rep. Roy serves not only to represent his constituents but also to better the lives of all Americans by exposing and fighting against the status quo Washington ways that have put us $22 trillion in debt and left us more burdened by government than our founding fathers ever could have imagined.

FreedomWorks is proud to announce that our bill of the month for June 2019 is the Prescription Drug Price Transparency Act, H.R. 1035, sponsored by Rep. Doug Collins (R-Ga.). The Prescription Drug Price Transparency Act would require greater transparency and accountability from pharmacy benefit managers (PBMs). This would lower prices for patients, families, and caregivers across the United States.

The small area of sanity in our healthcare sector is now under threat, however. A new proposal by the Department of Health and Human Services (HHS), referred to as the International Pricing Index (IPI), would dramatically undermine American leadership in pharmaceutical innovation and risk patient access to life-changing and life-saving treatments.